AU5682900A - Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments - Google Patents

Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Info

Publication number
AU5682900A
AU5682900A AU56829/00A AU5682900A AU5682900A AU 5682900 A AU5682900 A AU 5682900A AU 56829/00 A AU56829/00 A AU 56829/00A AU 5682900 A AU5682900 A AU 5682900A AU 5682900 A AU5682900 A AU 5682900A
Authority
AU
Australia
Prior art keywords
medicaments
metabolism
influence
combination
active agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56829/00A
Inventor
Rudi Grutzmann
Ulrich Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU5682900A publication Critical patent/AU5682900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU56829/00A 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments Abandoned AU5682900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19929012 1999-06-25
DE19929012A DE19929012A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and metabolically active drug
PCT/EP2000/005575 WO2001000189A2 (en) 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Publications (1)

Publication Number Publication Date
AU5682900A true AU5682900A (en) 2001-01-31

Family

ID=7912418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56829/00A Abandoned AU5682900A (en) 1999-06-25 2000-06-16 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Country Status (3)

Country Link
AU (1) AU5682900A (en)
DE (1) DE19929012A1 (en)
WO (1) WO2001000189A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200502496B (en) * 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
AU2003241907A1 (en) * 2002-05-31 2003-12-19 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydropyran derivative
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc Ester derivative and medicinal use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP2037929A4 (en) * 2006-06-02 2010-02-17 Univ San Diego State Res Found Compositions and methods for ameliorating hyperlipidemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
AU748608B2 (en) * 1997-05-01 2002-06-06 Bristol-Myers Squibb Company MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
DE19929012A1 (en) 2000-12-28
WO2001000189A3 (en) 2001-08-02
WO2001000189A2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
HUP0203563A3 (en) Fungicidal combinations of active substances and use thereof
PL356066A1 (en) Caspase inhibitors and uses thereof
IL147296A0 (en) Imidazoimidazoles and triazoles as anti-inflammatory agents
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
IL206621A0 (en) Caspase inhibitors and pharmaceutical compositions containing the same
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
HUP0100900A3 (en) Pharmaceutically active morpholinol and medicaments containing them
IL138153A0 (en) Methods and devices for delivering aerosolized active agents
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
PL349355A1 (en) Diaryl derivatives and their application as therapeutic agents
EP1419785A4 (en) Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
EP1067130A4 (en) Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient
AU1164601A (en) Therapeutic use and formulation
AU2001286242A1 (en) Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
HUP0200096A3 (en) Steroid sulfatase inhibitors and using the same
AU5682900A (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
AU5220800A (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
HK1044947A1 (en) Benzamide derivatives and drugs containing the same
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
HK1049329B (en) Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors
ZA981782B (en) The use of levobupivacaine in combination with other drugs
AU2001262699A1 (en) Biologically active agents and drugs

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase